• Avraham Pharmaceuticals Ltd., of Jerusalem, raised $3 million from Yissum Research Development Co. Ltd., the technology transfer arm of the Hebrew University of Jerusalem, and other investors. The funding will be used for an ongoing Phase II trial of ladostigil in Alzheimer's disease and a planned study of the drug in mild cognitive impairment. Ladostigil is a cholinesterase and brain-selective monoamine oxidase inhibitor. Avraham raised $9 million last year. Additional investors in the company include Pontifax, Clal Biotechnology Industries, Technion Research and Development Foundation Ltd., Professor Marta Weinstock-Rosin and others.

• Cadence Pharmaceuticals Inc., of San Diego, said it plans to sell $75 million worth of shares in a public offering. Terms have not yet been disclosed. Deutsche Bank Securities Inc. is acting as book-running manager and Leerink Swann LLC is acting as lead manager. Shares of Cadence (NASDAQ:CADX) fell $1.09, or 21.5 percent, to close at $3.97 on Monday.

• Lexicon Pharmaceuticals Inc., of The Woodlands, Texas, said it is planning a $163 million rights offering in which shareholders would receive nontransferable subscription rights to purchase up to 144.2 million shares of common stock. Investors would receive one right for each share owned, and each right would entitle them to buy a pro rata number of shares of common stock for $1.13 per share. The offering is being conducted at the election of two of Lexicon's largest shareholders. Shares of Lexicon (NASDAQ:LXRX) fell 15 cents, or 12.9 percent, to close at $1.01 on Monday.